Sun Pharmaceuticals Industries Ltd Q1FY18
Consolidated Results Q1FY18: (Rs. in crore)
|EBITDA Margin (%)||22.7||[1,462]|
|Net Loss (Un-adjusted)||321||-|
View Sun Pharma.Inds.
Last updated on
Sun Pharmaceutical Industries Ltd.'s Q1FY18 consolidated results for the quarter registered a miss versus street estimates. Revenue for the quarter came in 13.1 % lower than the estimated figure of Rs. 7096 crore. EBITDA for the quarter came in 19.7 % lower than the estimated figure of Rs. 1745 crore. And lastly, net profit for the quarter came in 128 % lower than the estimated figure of Rs. 1144 crore.
Sun Pharmaceutical Industries Ltd. consolidated revenue for the quarter came in at Rs. 6167 crore, registering 23% yoy decline.
EBITDA for the quarter fell by 53.2% yoy to Rs. 1400. crore with a corresponding margin contraction of 1462 bps. EBITDA margin for the quarter stood at 22.7%. This margin contraction was driven by 14.3% yoy increase in cost of raw materials consumed.
Company reported net loss of Rs.321 crore, vs net profit of Rs.2268 crore in Q1FY17. This was due to one-time exceptional provisions of Rs.950 crore on account of settlements with Apotex Corporation and retail purchasers.
Sun Pharmaceuticals Industries Ltd ended at Rs. 451.30, down by 8.85 points or 1.92% from its previous closing of Rs. 460.15 on the BSE.
The scrip opened at Rs. 460.90 and touched a high and low of Rs. 463.75 and Rs. 445.05 respectively. A total of 85,43,988(NSE+BSE) shares were traded on the counter. The stock traded above its 200 DMA.